Join our daily newsletter At The Bell to receive exclusive market insights
- INOVIQ (IIQ) receives a US patent that covers its SubB2M technology and provides intellectual property protection in the US for diagnostic applications
- The patent is titled “Subtilase cytotoxin B subunit mutant” and was issued to Griffith University and the University of Adelaide
- The SubB2M technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc which is found in multiple human cancers
- CEO Dr Leearne Hinch says the granting is an important achievement for the company as the US is the first market where the SubB2M tests are being commercialised as laboratory developed tests
- Shares in INOVIQ are up 14.1 per cent, trading at 44.5 cents as of 10:45 am AEST
INOVIQ (IIQ) has been granted a US patent that covers its SubB2M technology and provides intellectual property protection in the US for diagnostic applications.
The SubB2M technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc which is found in multiple human cancers including breast, ovarian and prostate.
The patent is titled “Subtilase cytotoxin B subunit mutant” and was issued to Griffith University and the University of Adelaide.
It expires on July 9, 2038 and claims modified SubB proteins capable of binding N-glycolylneuraminic acid (Neu5Gc) and variants and fragments thereof, such as SubB2M.
The US grant follows the company receiving an Australian grant for the same protection.
CEO Dr Leearne Hinch said the granting is an important achievement for the company as the US is the first market where the SubB2M tests are being commercialised as laboratory developed tests.
“INOVIQ has been making solid progress on the SubB2M program and we’re pleased to report that the performance of the SubB2M-CA15.3 assay for detection of breast cancer has been successfully replicated by ResearchDx,” she said.
“The assay is now undergoing optimisation and validation before advancing to clinical testing for breast cancer monitoring. This is an exciting step forward for the SubB2M
diagnostics program.”
Shares in Inoviq were up 14.1 per cent, trading at 44.5 cents as of 10:45 am AEST.
